Radical cell therapy tested for Tough-to-Treat lupus
NCT ID NCT06946485
Summary
This early-stage study is testing a new type of treatment called universal anti-CD70 CAR-T (CHT101) for people with severe lupus that hasn't responded to standard medications. It aims to see if this advanced cell therapy is safe and can effectively control the disease. The study will enroll about 15 adults whose lupus remains active despite trying multiple other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RECRUITINGNanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.